Looks like you’re on the UK site. Choose another location to see content specific to your location
GE Healthcare and Shine ally on radiopharmaceutical supply partnership
GE Healthcare has announced a supply chain collaboration project that aims to address radiopharmaceutical supply concerns in the medical imaging sector.
The companies have announced that they have successfully obtained pharmaceutical-grade Technetium-99m (Tc?99m) from GE Healthcare’s Drytec generator for the production of sodium pertechnetate for Tc99m injection, using molybdenum-99 (Mo-99) produced by Shine's processes.
Positive results of this test confirm that Mo-99 produced by the Shine process can be incorporated into the existing Mo-99 supply chain without changes to radiopharmacy practices or how the resulting Tc-99m is used in scanning procedures.
Shine is expected to begin commercial production in 2019 using this new process, and expects to be able to produce enough Mo?99 to supply two-thirds of the US patient population.
Jan Makela, general manager of core imaging at GE Healthcare Life Sciences, said: "Our customers – healthcare providers and imaging specialists – rely on a secure supply of molybdenum?99 to ensure that patients can get the diagnostic imaging scans they need."
Tc?99m is used in more than 40 million medical imaging procedures each year, primarily stress tests to assess heart disease and bone scans to determine the stage of cancer progression.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard